Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Janus

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Seminars in Dialysis|April 14, 2015
Anticancer Drugs in End-Stage Kidney Disease PatientsNicolas Janus, Vincent Launay-Vacher
International Journal of Clinical Pharmacy|October 26, 2023
How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendationsNicolas Janus, Pierre-Yves Desplanques
Expert Opinion on Drug Metabolism & Toxicology|May 25, 2017
Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysisNicolas Janus, Vincent Launay-Vacher
Nephrologie & Therapeutique|October 11, 2018
[Non-iodinated contrast media nephrotoxicity]Nicolas Janus, Vincent Launay-Vacher, Gilbert Deray
ESMO Open|November 16, 2016
Renal insufficiency and cancer treatmentsVincent Launay-Vacher, Nicolas Janus, Gilbert Deray
Bulletin Du Cancer|December 8, 2011
[Renal tolerance of targeted therapies]Juliette Thariat, Nicolas Janus, Jérôme Barrière, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 17, 2016
Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in FranceVincent Launay-Vacher, Nicolas Janus, Gilbert Deray, et al.
Annales De Biologie Clinique|December 5, 2015
[Reply to the article Non-VKA oral anticoagulants: an update for the clinical biologists]Nicolas Janus, Blandine Aloy, Gilbert Deray, et al.
Bulletin Du Cancer|June 20, 2016
[Renovascular effects of antiangiogenic drugs]Gilbert Deray, Nicolas Janus, Blandine Aloy, et al.
Bulletin Du Cancer|March 3, 2012
[Risk of cancer in patients following chronic dialysis and kidney graft]Nicolas Janus, Vincent Launay-Vacher, Jean-Marc Ferrero, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Seminars in Dialysis|April 14, 2015
Anticancer Drugs in End-Stage Kidney Disease PatientsNicolas Janus, Vincent Launay-Vacher
International Journal of Clinical Pharmacy|October 26, 2023
How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendationsNicolas Janus, Pierre-Yves Desplanques
Expert Opinion on Drug Metabolism & Toxicology|May 25, 2017
Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysisNicolas Janus, Vincent Launay-Vacher
Nephrologie & Therapeutique|October 11, 2018
[Non-iodinated contrast media nephrotoxicity]Nicolas Janus, Vincent Launay-Vacher, Gilbert Deray
ESMO Open|November 16, 2016
Renal insufficiency and cancer treatmentsVincent Launay-Vacher, Nicolas Janus, Gilbert Deray
Bulletin Du Cancer|December 8, 2011
[Renal tolerance of targeted therapies]Juliette Thariat, Nicolas Janus, Jérôme Barrière, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 17, 2016
Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in FranceVincent Launay-Vacher, Nicolas Janus, Gilbert Deray, et al.
Annales De Biologie Clinique|December 5, 2015
[Reply to the article Non-VKA oral anticoagulants: an update for the clinical biologists]Nicolas Janus, Blandine Aloy, Gilbert Deray, et al.
Bulletin Du Cancer|June 20, 2016
[Renovascular effects of antiangiogenic drugs]Gilbert Deray, Nicolas Janus, Blandine Aloy, et al.
Bulletin Du Cancer|March 3, 2012
[Risk of cancer in patients following chronic dialysis and kidney graft]Nicolas Janus, Vincent Launay-Vacher, Jean-Marc Ferrero, et al.
Pageof 5